ATP2A1 and myotonic dystrophy type 1: Treatment of control and DM1 patient-derived fibroblasts with ISOX or vorinostat at 5 μM for 2 days significantly increased MBNL1 levels (up to twofold), which was sufficient to significantly increase the inclusion of the ATP2A1 exon 22 and INSR exon 11 [68].